Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.

摘要: PURPOSETo compare two cisplatin based chemotherapy schedules in patients with advanced non-small-cell lung cancer (NSCLC).PATIENTS AND METHODSA total of 332 NSCLC were randomized to receive 80 mg/m2 on day 1 either combination teniposide 100 days 1, 3, and 5 (arm A) or paclitaxel 175 by 3-hour infusion B); cycles repeated every 3 weeks.RESULTSFifteen ineligible; patient characteristics well balanced between the arms: 71% male, had less than 5% weight loss, 89% a World Health Organization (WHO) performance status 0 51% adenocarcinoma, 61% stage IV disease. Hematologic toxicity was significantly more severe arm A (leukopenia, neutropenia, thrombocytopenia grade 4: 66% v 19%, 83% 55%, 36% 2% arms B, respectively), which resulted febrile neutropenia (27% 3% dose reductions, treatment delays. There total...